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Abstract
Background: Few controlled clinical trials exist to support oral combination therapy in pulmonary arterial
hypertension (PAH).
Methods: Patients with PAH (idiopathic [IPAH] or associated with connective tissue disease [APAH-CTD]) taking
bosentan (62.5 or 125 mg twice daily at a stable dose for ≥3 months) were randomized (1:1) to sildenafil (20 mg, 3
times daily; n = 50) or placebo (n = 53). The primary endpoint was change from baseline in 6-min walk distance
(6MWD) at week 12, assessed using analysis of covariance. Patients could continue in a 52-week extension study.
An analysis of covariance main-effects model was used, which included categorical terms for treatment, baseline
6MWD (<325 m; ≥325 m), and baseline aetiology; sensitivity analyses were subsequently performed.
Results: In sildenafil versus placebo arms, week-12 6MWD increases were similar (least squares mean difference
[sildenafil–placebo], −2.4 m [90% CI: –21.8 to 17.1 m]; P = 0.6); mean ± SD changes from baseline were 26.4 ± 45.7
versus 11.8 ± 57.4 m, respectively, in IPAH (65% of population) and −18.3 ± 82.0 versus 17.5 ± 59.1 m in APAH-CTD
(35% of population). One-year survival was 96%; patients maintained modest 6MWD improvements. Changes in
WHO functional class and Borg dyspnoea score and incidence of clinical worsening did not differ. Headache,
diarrhoea, and flushing were more common with sildenafil.
Conclusions: Sildenafil, in addition to stable (≥3 months) bosentan therapy, had no benefit over placebo for 12-
week change from baseline in 6MWD. The influence of PAH aetiology warrants future study.
Trial registration: ClinicalTrials.gov NCT00323297 (registration date: May 5, 2006).
Keywords: Sildenafil - Bosentan - pulmonary hypertension - randomized controlled trial -exercise test, Combination
therapy
Background
Pulmonary arterial hypertension (PAH) is a progressive,
ultimately fatal disease [1, 2]. Approved PAH-specific
therapies target 3 main biochemical pathways, offering
opportunities for treatment with prostacyclin analogues;
soluble guanylate cyclase (sGC) stimulators (riociguat
[3]) or phosphodiesterase type 5 (PDE5) inhibitors
(sildenafil and tadalafil); and endothelin receptor antago-
nists (ETRAs; bosentan, ambrisentan, and macitentan),
respectively [1, 2]. Individually, these therapies improve
clinical outcomes in patients with PAH in randomized
controlled studies [4]. However, few controlled studies
exist to support combination therapy.
International guidelines recommend sequential con-
comitant therapy, including (in any order) an ETRA, a
PDE5 inhibitor, and a prostanoid when clinical response
to initial monotherapy is inadequate [1, 4, 5] because of
the possibility of additive/synergistic effects [6], despite
limited supporting data. In meta-analysis of randomized
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controlled trials, dual concomitant therapy showed mod-
est improvement in exercise capacity versus monother-
apy (~22–25 m) in short-term (12–16 week) studies [7,
8]. Concomitant therapy with oral agents (eg, sildenafil
and bosentan) may appeal to patients more than con-
comitant therapy with intravenous, subcutaneous, or in-
haled prostanoids; however, few controlled trials have
assessed oral concomitant therapy in patients with PAH.
The results of a phase 2, open-label, noncomparative
study (COMPASS-1) found acute reduction of pulmon-
ary vascular resistance following the addition of a single
dose of sildenafil to stable bosentan therapy [9]; this
therapy was well tolerated in a 12-week, phase 4, open-
label study (COMPASS-3) of a bosentan-based stepped
approach with sildenafil in severe PAH [10, 11].
This was a 12-week evaluation of the safety and effi-
cacy of oral sildenafil or placebo when used in addition
to background oral bosentan therapy at a stable dose in
patients with PAH. We assessed whether concomitant
therapy would produce a greater improvement in exer-
cise capacity, as assessed by 6-min walk distance
(6MWD). Patients also could continue in a 52-week ex-
tension study.
Methods
Study design
A 12-week, multicentre, multinational, randomized,
double-blind study (Part A) was conducted between Sep-
tember 2006 and August 2012 at 29 sites in 10 countries
in patients with PAH who were receiving treatment with
bosentan at a stable dose for ≥3 months to evaluate the
additive effect of sildenafil therapy. The 52-week open-
label extension study (Part B) continued until August
2013. The study was managed by Pfizer Inc.
Patients were randomly assigned (via interactive voice-
response system incorporating a central randomization
and drug supply scheme) in a 1:1 ratio to sildenafil (20 mg
three times daily [TID]) or placebo for 12 weeks, adminis-
tered in addition to their existing bosentan therapy (per
standard of care). Patients and investigators were blinded
to treatment. Randomization was intended to be stratified
by baseline 6MWD (<325 m or ≥325 m) and aetiology
(idiopathic/heritable PAH [IPAH/HPAH] or other). How-
ever, after blinding was broken, it was realized that only
baseline 6MWD stratification had occurred. For the open-
label extension, patients who completed 12 weeks of
double-blind phase received sildenafil 20 mg TID in
addition to bosentan for an additional 52 weeks. The use
of the dosage of 20 mg TID was dictated by its approval
after the SUPER-1 study [12, 13].
The coordinating ethics committee that approved the
study was Comitato Etico Azienda Policlinico Umberto I
(Universita’ degli Studi di Roma La Sapienza, Viale del
Policlinico, 155, Roma 00155; reference number 1080/
2006). At each of the 29 study centers, local institutional
review boards or independent ethics committees add-
itionally approved the trial protocol according to local
and country specific guidelines. Written informed con-
sent was obtained from each patient.
Patients
Inclusion criteria for enrolment were adults (≥18 years)
with PAH (mean pulmonary artery pressure ≥ 25 mmHg;
pulmonary capillary wedge pressure of <15 mmHg at
rest) confirmed by right heart catheterization within the
previous 3 years and receiving treatment with bosentan
(62.5 or 125 mg twice daily) at a stable dose for
≥3 months. PAH was idiopathic, heritable, or associated
with connective tissue disease (CTD; restricted in some
countries to scleroderma), or surgical repair (≥5 years
previously) of septal defect (United States only). World
Health Organization (WHO) functional class (FC) before
initiation of bosentan therapy was III/IV (Australia and
United States), III (Czech Republic, France, Germany,
Greece, Italy, United Kingdom), or any FC (Israel and
Taiwan). Baseline 6MWD was ≥100 and ≤450 m. Pa-
tients were required to prevent pregnancy.
Exclusion criteria were acutely decompensated heart
failure within 30 days before randomization; left ven-
tricular (LV) ejection fraction of <45% or LV shortening
fraction of <0.2 within 3 months before randomization;
congenital heart disease (unless meeting US inclusion
criteria); history of myocardial infarction, stroke, or atrial
septostomy within 6 months before randomization; un-
controlled brady- or tachy-arrhythmias, placement of
pacemakers/implantable defibrillators <60 days before
randomization; history of verified pulmonary embolism;
history of chronic/restrictive lung disease (eg, COPD or
scleroderma) with TLC <60% and/or FEV1 ≤ 80% pre-
dicted within 30 days of randomization; change of dose/
class of standard background PAH therapy (ie, oxygen,
calcium channel blockers, digoxin, diuretics) within
30 days (except oral anticoagulant therapy to maintain
international normalized ratio within the therapeutic
range); current chronic PAH-specific therapy (eg, prosta-
cyclin, PDE5 inhibitors, ETRAs other than bosentan), ni-
trates/nitric oxide donors including nicorandil, or any
potent cytochrome P450 3A4 (CYP3A4) inhibitors [eg,
cyclosporin A, glibenclamide]); congenital heart disease
(unless fulfilling US inclusion criteria), pulmonary hyper-
tension due to thromboembolism, HIV, or schistosomia-
sis; previous failure on sildenafil or bosentan (defined as
no evidence of clinical improvement and, on discontinu-
ation, no worsening in symptoms/clinical status); im-
paired renal function (serum creatinine >2.5× upper
limit of normal [ULN]); and severe hepatic impairment
(alanine or aspartate transaminase >3× ULN) or porto-
pulmonary hypertension.
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Outcome measures and statistical considerations
At all post-baseline visits in the double-blind study
(weeks 4, 8, and 12 or end of treatment) and at weeks
28, 40, 52, and 64 of the extension (but not at week-16
visit), 6MWD, WHO FC, [14] and Borg dyspnoea score
(0 [no breathlessness] to 10 [maximum breathlessness])
[15, 16] were assessed. Clinical worsening (death, lung
transplantation, hospitalization due to pulmonary hyper-
tension, or clinical deterioration of PAH requiring add-
itional therapy) was assessed at weeks 4, 8, and 12. In
case of clinical worsening, the need to add a new specific
treatment during the open-label phase of the study was
left to each investigator following the local strategy.
Survival was assessed at week 64, including patients
who had discontinued treatment. Blood samples were
collected for analysis of plasma sildenafil and bosentan
concentrations and metabolites on day 1 and week 12,
with additional samples collected near trough time
points at weeks 4 and 8, and for analysis of brain natri-
uretic peptide (BNP) and N-terminal pro-BNP at weeks
4, 12, and 64. The 6MWD was to be performed as close
to trough levels of sildenafil and peak levels of bosentan
as possible.
The primary endpoint was the treatment difference in
change from baseline in 6MWD at week 12 (intent-to-
treat population). The analysis of covariance (ANCOVA)
main-effects model was used, including categorical terms
for treatment, baseline 6MWD (<325 m; ≥325 m), and
baseline aetiology; missing values were imputed using
last-observation-carried-forward method; the same ap-
proach was used to assess week-64 data. To support in-
terpretation of the primary analysis, sensitivity analyses
were performed, including an ANCOVA on the per-
protocol population, nonparametric analysis (stratified
Wilcoxon test [Van Elteren]), and ANCOVA using mul-
tiple imputation approaches (informative missing, miss-
ing at random) for missing week-12 data.
There were several secondary and tertiary endpoints.
Potential heterogeneity of the treatment effect in the pri-
mary endpoint across different levels of each stratifica-
tion factor was investigated in separate ANCOVA
models that included categorical terms of treatment ef-
fect, baseline 6MWD, and aetiology with adjustment of
interaction terms “treatment*baseline walk distance” or
“treatment*aetiology.” Because of a randomization strati-
fication error, the population was stratified by baseline
6MWD only (not by aetiology). Therefore, for change
from baseline 6MWD at week 12, statistical analyses for
treatment comparison with adjustment of baseline
6MWD (the actual stratification factor) without adjust-
ment of baseline aetiology were performed to evaluate
the impact of the randomization stratification error.
Change from baseline in 6MWD at week 12 was
assessed in an exploratory post-hoc assessment in
groups stratified by pre-randomization bosentan treat-
ment duration (≤1 vs >1 y); ANCOVA analyses were
performed including treatment, baseline 6MWD, and
aetiology as well as the interaction term “treatment*prior
bosentan duration.”
For WHO FC, Borg dyspnoea score, and time to clin-
ical worsening, statistical analysis was to be conducted
using a step-down procedure contingent upon statistical
significance of the primary endpoint; otherwise, simple
summary statistics are presented. Summary statistics are
provided for the tertiary endpoints of change from base-
line in BNP and pro-BNP. Pharmacokinetic analyses
were completed for sildenafil and bosentan to investigate
potential drug-drug interactions in the study population.
Adverse events (AEs), monitored throughout the study,
were coded using Medical Dictionary for Regulatory Ac-
tivities (v15.0) and assessed for severity and relation to
treatment.
The estimated sample size was based on the primary
endpoint, change from baseline in 6MWD at week 12.
Assuming a mean 30-m treatment difference for the sil-
denafil plus bosentan arm versus placebo plus bosentan
arm and a standard deviation of 60 m (from SUPER-1
study assessing sildenafil monotherapy in adults with
PAH [12]), a sample size of 51 patients per arm was re-
quired to detect a treatment difference with 80% power
at 1-sided significance level of 0.05. Assuming a 15%
dropout rate between screening and randomization and
a 4% dropout rate after randomization (SUPER-1 [12]),
approximately 128 patients were to be screened to en-
sure approximately 106 randomized and 102 evaluable
patients in 2 treatment arms.
Results
Of 104 randomized patients, 103 were treated in the
double-blind study and 91 continued in the extension
(Fig. 1). Most patients were women, and 34% and 65%
were WHO FC II and III, respectively; the
randomization stratification error caused an imbalance
in baseline 6MWD between treatment groups among
the 4 strata (aetiology and 6MWD; Table 1). The most
common concomitant therapies in the sildenafil and pla-
cebo groups were furosemide (58% and 47%, respect-
ively), warfarin/warfarin sodium (36% and 28%),
spironolactone (32% and 32%), paracetamol (20% and
32%), and allopurinol (22% and 23%). Among patients
with CTD 7/15 (46%) of the patients in the sildenafil
group and 12/21(57%) in the placebo group were treated
with prednisone or prednisolone. More patients in the
placebo group had current cardiac disorders (19 [36%];
sildenafil, 14 [28%]), whereas more patients in the sil-
denafil group had current respiratory/thoracic/medias-
tinal disorders (25 [50%]; placebo, 15 [28%]).
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The change from baseline in 6MWD at week 12 was
similar between the sildenafil (13.6 m) and placebo
(14.1 m) arms (LS mean difference for sildenafil – placebo,
−2.4 m [90% CI: –21.8 to 17.1 m]; P = 0.6; Fig. 2). Per-
protocol (n = 42 patients/arm) and other sensitivity ana-
lyses produced similar results (data not shown). An im-
provement of ≥30 m was experienced by 34% of sildenafil-
treated (n = 17) and 34% of placebo-treated (n = 18) pa-
tients; a > 30-m worsening was seen in 10% (n = 5) and
11% (n = 6), respectively. At week 64, the change from
baseline in 6MWD was numerically improved with con-
comitant sildenafil and bosentan therapy (Fig. 2).
Because there was no statistically significant treatment
effect in the primary week-12 6MWD analysis, second-
ary and tertiary endpoints were considered exploratory;
simple summaries are provided. The change from base-
line in 6MWD at week 12 differed by aetiology and by
pre-randomization duration of bosentan exposure
(Fig. 3). Sildenafil-treated patients with APAH-CTD had
a decline in 6MWD, as did patients with ≤1 year of
bosentan exposure at enrolment, whereas placebo-
treated patients had improved 6MWD.
The median change in Borg dyspnoea score, BNP and
pro-BNP values, and shifts from baseline in WHO FC were
similar between treatment arms (Table 2). Population phar-
macokinetic results showed concomitant administration of
bosentan resulted in a 72.69% (95% CI, 66.30%–77.76%) de-
crease in sildenafil exposure, while concomitant administra-
tion of sildenafil produced a 19.66% (95% CI, 9.83%–
30.76%) increase in bosentan exposure.
In the double-blind phase, 2 patients in each arm had clin-
ical worsening events (hospitalization due to PAH); 1 add-
itional patient in the sildenafil arm died (sudden death). In
the extension study, the Kaplan-Meier estimate of 1-year
survival from the time of randomization was 96% (90% CI,
88%–99%) for both the sildenafil and placebo arms and 96%
(90% CI, 87%–99%) from the start of sildenafil treatment
(delay of 12 weeks in patients randomized to placebo).
In the double-blind phase, treatment-related AEs, pre-
dominantly mild to moderate, were more common in
sildenafil-treated patients. No unexpected AEs occurred
(Table 3). Two patients (sildenafil arm) had serious treat-
ment-related AEs (acute coronary syndrome superimposed
on pre-existing 3-vessel coronary disease and underlying
Fig. 1 Patient disposition (CONSORT diagram). AE=adverse event
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diabetes mellitus/hypertension, in whom a possible con-
tributory role of sildenafil could not be excluded because of
temporal association in 1 patient; the second was hypoxia
deemed related by the investigator but not the sponsor).
Two patients from the sildenafil group died during treat-
ment (1 sudden death [double-blind phase] and 1 pulmon-
ary hypertension [open-label phase]); 6 patients died during
follow-up (sildenafil: pancreatic neoplasm, arrhythmia; pla-
cebo: pulmonary hypertension [n = 3] and sudden cardiac
death).
Discussion
In this multinational, double-blind study, the change
from baseline in 6MWD at week 12 (primary endpoint)
Table 1 Baseline demographics and clinical characteristics
Placebo (n = 53) Sildenafil (n = 50)
Men, n (%) 12 (23) 13 (26)
Age, mean ± SD, y 56.9 ± 14.1 55.2 ± 15.1
Ethnicity, n (%)
White 45 (85) 44 (88)
Asian 2 (4) 4 (8)
Other or unspecified 6 (11) 2 (4)
Primary diagnosis, n (%)
IPAH/HPAH 32 (60) 35 (70)
Duration since diagnosis, median (range), y 1.3 (0.3–10.5) 1.5 (0.4–19.3)
APAH-CTD 21 (40) 15 (30)
Duration since diagnosis, median (range), y 2.0 (0.3–8.1) 1.5 (0.3–7.2)
Scleroderma 19 10
Othera 2 5
Bosentan treatment
Dosage, n (%)
62.5 mg BID 3 (6) 2 (4)
125 mg BID 49 (93) 47 (94)
Other or missing 1 (2) 1 (2)
Duration, median (range), mo 11.4 (3.1–90.9) 11.2 (3.2–65.3)
≤ 1 y, n (%) 27 (51) 26 (52)
> 1 y, n (%) 26 (49) 24 (48)
6MWD, mean ± SD, m 350.4 ± 87.6 354.4 ± 73.1
<325 m, n (%) 17 (32) 15 (30)
≥325 m, n (%) 36 (68) 35 (70)
Strata (aetiology, baseline 6MWD), n (%)
IPAH/HPAH, <325 m 7 (13) 10 (20)
IPAH/HPAH, ≥325 m 25 (47) 25 (50)
APAH-CTD, <325 m 10 (19) 5 (10)
APAH-CTD, ≥325 m 11 (21) 10 (20)
WHO functional class, n (%)
II 15 (28) 20 (40)
III 38 (72) 29 (58)
IV 0 1 (2)
Borg dyspnoea score, mean ± SD, median (range) 4.2 ± 1.9 4.0 (0.5–8.0) 4.1 ± 2.3 4.0 (0–8.0)
mPAP, mean ± SD, mmHg 44.9 ± 13.3 46.9 ± 12.5
6MWD 6-min walk distance, APAH-CTD connective tissue disease-associated PAH, IPAH/HPAH idiopathic/heritable PAH, mPAP mean pulmonary artery pressure, PAH
pulmonary arterial hypertension, WHO World Health Organization
aIncludes (n = 1 each) mixed connective tissue disease and Sharp syndrome in the placebo group; and CREST syndrome, rheumatoid arthritis, Sharp syndrome,
Sjögren syndrome, and Takayasu’s disease in the sildenafil group
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was similar between the sildenafil and placebo arms in
patients with PAH receiving bosentan at a stable dose
for ≥3 months. Subanalyses suggested that the 6MWD
response differed by PAH aetiology and pre-
randomization duration of bosentan exposure. Changes
in Borg dyspnoea scores, WHO functional class, and
BNP and pro-BNP, as well as the incidence of clinical
worsening, were similar between the 2 arms. No new or
unexpected AEs occurred with sildenafil and bosentan
concomitant treatment. The disappointing efficacy re-
sults were not explained by the minor randomization
stratification error that resulted in slight imbalances in
PAH aetiology between the 2 arms or by patient baseline
comorbidities (data not shown). As discussed below, we
suggest that the main reasons for the negative findings
may be that patients were not truly stable on bosentan
therapy at the time of randomization to sildenafil or pla-
cebo and that patients did not receive sufficient sildena-
fil exposure because of the drug-drug interaction with
bosentan.
In our study, patients who received placebo in addition
to bosentan therapy continued to improve throughout
the 12-week double-blind phase, which likely affected
the ability to attain a significant treatment difference in
6MWD (primary endpoint). Similarly, the nonsignificant
placebo-corrected treatment effect in 6MWD at week 16
in patients receiving background bosentan in the pivotal
randomized, double-blind, placebo-controlled, tadalafil
study [17] occurred because of improvement from base-
line in the placebo arm (mean, 19 m); the improvement
in 6MWD in patients receiving background bosentan
plus tadalafil (mean, 40 m) was similar to that in patients
receiving tadalafil monotherapy (mean, 42 m). Although
improved compliance with bosentan within the con-
trolled study or bias because of failure to blind bosentan
treatment may have affected the outcome, the authors
postulated that improvement in placebo patients receiv-
ing bosentan could be attributed to continued improve-
ment with longer bosentan exposure [17]. Our study
similarly contrasts with the early indication that the
maximal effect of bosentan on 6MWD is achieved
within the first 3–4 months of therapy [18] and supports
the idea that the definition of stable therapy should be
re-evaluated for future studies [17]. Although small
(n ≤ 32), largely uncontrolled studies have shown
Fig. 2 Mean (±SE) change from baseline to week 12 and week 64 in
6MWD. Last observations were carried forward. Patients are shown by
their randomization in the 12-week double-blind study; however, in
the 52-week open-label extension (after week 12), all patients received
sildenafil and bosentan concomitant therapy. 6MWD=6-minute
walk distance
Fig. 3 Mean (±SE) change from baseline to week 12 in 6MWD by
aetiology (a), baseline 6MWD (b), and prior bosentan therapy duration
(c). Last observations were carried forward. 6MWD=6-minute walk
distance; APAH-CTD=connective tissue disease-associated PAH; IPAH/
HPAH=idiopathic/heritable PAH; LS=least squares; PAH=pulmonary
arterial hypertension
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positive effects of sildenafil and bosentan concomitant
therapy on various outcomes in PAH (Table 4), a com-
parison of the results of these studies with those of the
present study is difficult because of different study de-
signs, patient populations (PAH aetiology, functional
class), and dosing regimens.
The pharmacokinetic analysis in the current study in-
dicated a substantial drug-drug interaction, with sildena-
fil exposure decreased by 73% and bosentan exposure
increased by 20% with concomitant administration.
Bosentan is a CYP3A4 inducer, whereas the PDE5 in-
hibitor sildenafil is a CYP3A4 substrate. [19] Although
Table 2 Secondary and tertiary efficacy endpoints
Change from baseline at week 12 Change from baseline at week 64 Change from week 12 to week 64
Endpoint Placebo (n = 53) Sildenafil (n = 50) Placebo
(n = 53)
Sildenafil (n = 50) Placebo (n = 48) Sildenafil (n = 43)
Borg dyspnoea score (LOCF)
n 53 49 53 49 47 36
Median change (range) 0 (−3, 6) 0 (−6, 2) 0 (−3, 7) 0 (−4, 4) 0 (−7, 8) 0 (−2, 4)
WHO functional class (LOCF), n (%)
Worsened 1 class 1 (2) 0 (0) 4 (8) 5 (10) 4 (8) 8 (19)
No change 45 (85) 39 (78) 34 (64) 34 (68) 34 (71) 28 (65)
Improved 1 class 7 (13) 10 (20) 15 (28) 10 (20) 9 (19) 3 (7)
Died 0 1 (2) 0 1 (2) 0 1 (2)
Missing 0 0 0 0 1 (2) 3 (7)
BNP
n 35 33 24 18 21 21
Median change (min, max),
pg/mL
8.0 (−217.5,
254.4)
−1.0 (−436.5,
268.7)
3.0 (−125.4,
738.0)
34.3 (−618.2,
1141.8)
−6.1 (−166.9,
652.0)
20.1 (−643.7,
1218.8)
N-terminal pro-BNP
n 14 19 9 10 9 12
Median change (min, max),
pg/mL
14.3 (−2227.0,
600.0)
−94.1 (−1277.0,
221.0)
7.8 (−1761.0,
561.3)
−121.7 (−895.3,
5519.4)
55.0 (−1029.0,
466.0)
−13.2 (−459.4,
5656.2)
BNP brain natriuretic peptide, LOCF last observation carried forward, WHO World Health Organization
Table 3 Adverse events
Adverse events (AEs)a Placebo (n = 53) Sildenafil (n = 50)
All causality Treatment related All causality Treatment related
Patients with AEs, n (%) 41 (77) 13 (25) 34 (68) 17 (34)
Patients with serious AEs, n (%) 12 (23) 0 9 (18) 1 (2)
AEs
Headache 5 (9) 3 (6) 6 (12) 6 (12)
Flushing 1 (2) 1 (2) 5 (10) 5 (10)
Diarrhoea 3 (6) 1 (2) 5 (10) 3 (6)
Nasopharyngitis 5 (9) 0 4 (8) 0
Vertigo 0 0 3 (6) 0
Vision blurred 0 0 3 (6) 2 (4)
Oedema, peripheral 2 (4) 1 (2) 3 (6) 1 (2)
Pulmonary arterial hypertension 5 (9) 0 2 (4) 0
Back pain 4 (8) 0 1 (2) 0
Bronchitis 4 (8) 0 1 (2) 0
Upper respiratory tract infection 3 (6) 0 1 (2) 0
Nausea 4 (8) 2 (4) 0 0
aAdverse events in ≥5% of patients in either treatment group during double-blind treatment with bosentan + placebo or bosentan + sildenafil
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sildenafil is not an inhibitor of CYP3A, it interferes with
the hepatic uptake transporters OATP1B1/1B3 for which
bosentan is a substrate [19]. In healthy volunteers, con-
comitant administration increased the bosentan plasma
concentration (area under the curve) by ~50% and de-
creased the sildenafil plasma concentration by ~60%
[20]. Similar results were described in patients with PAH
treated concomitantly with these two therapies [21].
Concomitant therapy with an ETRA and a PDE5 inhibi-
tor has shown some potential for clinical efficacy in PAH.
In a randomized, double-blind study of patients (n = 124)
who received tadalafil or placebo added to stable ambri-
sentan therapy for 16 weeks, patients receiving concomi-
tant therapy had significantly improved 6MWD and
significantly fewer clinical worsening events than patients
receiving placebo, with no increase in AEs [22]. Further-
more, the risk of clinical failure and 24-week 6MWD were
significantly improved with up-front concomitant therapy
with ambrisentan and tadalafil versus monotherapy in 500
treatment-naive patients with PAH [23]. A phase 4 study
(COMPASS-2), in which patients receiving sildenafil were
randomized to bosentan or placebo, demonstrated a sig-
nificant improvement in week-16 6MWD (exploratory
analysis) with sildenafil-bosentan concomitant therapy
versus sildenafil-placebo, but no significant treatment dif-
ference was observed in time to first morbidity/mortality
event (primary endpoint) [24].
The 6MWD has been a primary endpoint in registra-
tion studies of all but two of the approved PAH therap-
ies; however, some studies have noted that changes in
6MWD do not correlate with long-term outcomes [25,
26], and the clinical relevance of short-term changes is
unclear [27]. Hemodynamic parameters, which were not
assessed during the current study, may have provided
additional insights on clinical outcomes.
Taking into account the results of studies evaluating
the combination of a PDE-5i and an ERA, the variability
could be explained by the pharmacokinetic interaction
of some combination (bosentan-sildenafil) or the behav-
iour of placebo group (our study, PHIRST). Even in the
absence of head to head comparison, one could specu-
late that the drugs in the same class are not similar and
may not be interchangeable without clinical impact. Fi-
nally, it seems that the choice of the combination and
the timing of intervention could have a role in the treat-
ment strategy of PAH.
Important clinical questions on combination therapy
timing remain unanswered, including whether concomi-
tant therapy should be initial or sequential. Additional
controlled trials of add-on therapy in patients with PAH
are needed. The influence of PAH aetiology on efficacy
outcomes with concomitant therapy and the duration of
background therapy should be taken in account for the
design of further study.
Although our study was placebo controlled, several
factors limit the conclusion that this combination, rec-
ommended by international guidelines [5, 28], is not
clinically effective. First, sample size calculations were
based on observations in treatment-naïve patients re-
ceiving sildenafil monotherapy [12], and in retrospect,
this level of 6MWD improvement appears optimistic.
Second, patients who are already receiving effective
bosentan monotherapy likely have decreased potential
for improvement (ie, a ceiling effect). Finally, the enrol-
ment was slow, and changes in therapeutic strategies
could have influenced the results of the present study.
Conclusions
In this multinational trial of predominantly WHO FC II and
III PAH patients, sildenafil was well tolerated, but provided
no additional benefit versus placebo on week-12 6MWD
when used in addition to stable (≥3 months) bosentan ther-
apy. Study limitations, including the definition of stable ther-
apy, and study results demonstrating the importance of
drug-drug interactions should be helpful in the design of fu-
ture clinical trials of concomitant therapies for PAH.
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screened subjects. (PDF 105 kb)
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